title: Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
abstract: Rituximab in combination with chlorambucil or radiation therapy may be an effective and less-toxic therapeutic alternative for patients with lymphocyte predominance Hodgkin's disease (LPHD). We treated 6 patients with LPHD with weekly rituximab at 375 mg/m2 for 4 weeks, followed by either radiation therapy or chlorambucil. Four patients had previously untreated disease and 2 had relapsed LPHD. All patients had no evidence of disease progression at a median follow-up time of 12.5 months after receiving rituximab therapy (range, 6-39 months) and a median follow-up time of 6.5 months after completion of chlorambucil or radiation therapy (range, 3-25 months). Further follow-up is warranted to evaluate response duration and late toxicity of this novel treatment strategy
authors.affiliation: Division of Medical Oncology and transplantation, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Valerie K
authors.initials: VK
authors.lastname: Ibom
authors.forename: Robert G
authors.initials: RG
authors.lastname: Prosnitz
authors.forename: Jerald Z
authors.initials: JZ
authors.lastname: Gong
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Moore
authors.forename: Carlos M
authors.initials: CM
authors.lastname: DeCastro
authors.forename: Leonard R
authors.initials: LR
authors.lastname: Prosnitz
authors.forename: David A
authors.initials: DA
authors.lastname: Rizzieri
authors.forename: Jon P
authors.initials: JP
authors.lastname: Gockerman
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008214:Lymphocytes / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D002699:Chlorambucil; D000069283:Rituximab